Loading clinical trials...
Loading clinical trials...
CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults
Conditions
Interventions
Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
Locations
1
United States
Magee Women's Hospital of UPMC
Pittsburgh, Pennsylvania, United States
Start Date
January 1, 2015
Primary Completion Date
December 1, 2015
Completion Date
March 1, 2016
Last Updated
September 8, 2017
NCT06741631
NCT06741618
NCT07072481
NCT03135886
NCT06367348
NCT04466488
Lead Sponsor
International Partnership for Microbicides, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions